Schaeffer's Top Stock Picks for '25

bluebird bio Stock Bounces on Cancer Drug Update

Much of the stock's recent support stemmed from the rising 160-day moving average

Managing Editor
Jun 4, 2018 at 9:53 AM
facebook X logo linkedin


Biotech concern bluebird bio Inc (NASDAQ:BLUE) is higher in today's trading after the company reported data for its immunotherapy drug bb2121, which showed cancer patients survived for a median of roughly 12 months after receiving the treatment before their conditions worsened. In response, BLUE is 2.4% higher to trade at $186.80.

This price action is more of the same for bluebird stock, as the shares have enjoyed support from the 160-day moving average since early April, and over the past 12 months have gained almost 130%. They still have some ground to make up, however, to revisit their record high of $236.17 on March 13.

Analyst sentiment is mostly bullish. Of the 20 firms covering BLUE, 13 currently hold "strong buy" ratings. Further, the stock's average 12-month price target stands at $216.67 -- a 16% premium to current levels.

On the other hand, short interest is elevated. Although short interest on BLUE fell almost 5% during the most recent reporting period, it still accounts for 7.8% of the equity's total available float, or seven times bluebird bio stock's average daily trading volume.

Echoing this skepticism, BLUE's Schaeffer's put/call open interest ratio (SOIR) of 1.06 ranks higher than 97% of all comparable readings taken in the past year. In other words, options traders are more put-heavy than usual among contracts set to expire in three months or less.
 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?